SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc. today announced that an open-label, phase 1 clinical trial designed to evaluate the safety and tolerability of FG-3019, a fully human monoclonal antibody against connective tissue growth factor (CTGF), in combination with gemcitabine and erlotinib in patients with locally advanced or metastatic pancreatic cancer has commenced.
